(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 25.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Vericel's revenue in 2025 is $237,224,000.On average, 3 Wall Street analysts forecast VCEL's revenue for 2025 to be $14,339,267,233, with the lowest VCEL revenue forecast at $14,253,819,272, and the highest VCEL revenue forecast at $14,418,718,846. On average, 3 Wall Street analysts forecast VCEL's revenue for 2026 to be $18,500,233,161, with the lowest VCEL revenue forecast at $17,524,327,498, and the highest VCEL revenue forecast at $19,448,655,561.
In 2027, VCEL is forecast to generate $23,917,184,180 in revenue, with the lowest revenue forecast at $23,313,801,646 and the highest revenue forecast at $24,520,566,713.